Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Gene Therapy Coverage Update | Ope…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy MP 5.01.47

    Gene Therapies for Treatment of Wounds in Dystrophic Epidermolysis Bullosa

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.47 alerts

    Get alerted when Policy MP 5.01.47 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for beremagene geperpavec-svdt (Vyjuvek) and prademagene zamikeracel (Zevaskyn) for treatment of wounds in individuals with recessive dystrophic epidermolysis bullosa (RDEB). Affects providers prescribing or administering these therapies and members receiving them.

    Policy Summary
    PayerBluecross Idaho
    PolicyGene Therapies for Treatment of Wounds in Dystrophic Epidermolysis Bullosa
    Policy CodePolicy MP 5.01.47
    Change TypeMaterial additions and updates (Vyjuvek criteria expandedZevaskyn added)
    Effective DateApr 1, 2026
    Last ReviewJun 1, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain prior authorization and submit documentation confirming genetic COL7A1 mutation status, wound size/duration/stage, and product-specific limits prior to treatment.
    SourceLink
    POLICY UPDATE CHANGES

    Relevant information and policy statements for prademagene zamikeracel (Zevaskyn) were added following FDA approval in April 2025; Zevaskyn may be considered medically necessary for RDEB when specified criteria and limits are met.

    Additional criteria for Vyjuvek (beremagene geperpavec-svdt) were added.

    Policy updated with literature review through June 1, 2025, and references on new therapies and trials were added.

    6 moInitial auth (Vyjuvek)
    12 mo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Reauth (Vyjuvek)
    12 sheetsZevaskyn qty limit
    6 moZevaskyn duration
    6 moMinimum age (Vyjuvek)
    Jun 1, 2025Last literature update

    Coverage Criteria and Medical Necessity

    Initial Therapy - Beremagene geperpavec-svdt (Vyjuvek)

    Covered when ALL of the following are met:

    Vyjuvek initial criteria: 1) Patient is ≥ 6 months of age; 2) Diagnosis of dystrophic epidermolysis bullosa confirmed by documented biallelic pathogenic COL7A1 mutation(s) and presence of clinical manifestations (chronic/recurring wounds, blistering, mucosal involvement); 3) Positive NC1 expression in skin where specified by testing (per diagnostic documentation); 4) Medication is prescribed by or in consultation with a dermatologist or provider who specializes in dystrophic epidermolysis bullosa or wound care; 5) Patient is not pregnant or breastfeeding and has no active infection, active squamous cell carcinoma, or history of squamous cell carcinoma in the targeted wound(s); 6) Medication will be administered at FDA‑approved dosing by a healthcare professional (see Policy Guidelines).

    Initial authorization period: 6 months.

    Continuation Therapy - Beremagene geperpavec-svdt

    Reauthorization covered when ALL of the following are met:

    Vyjuvek continuation criteria: 1) Patient continues to meet the initial treatment criteria as listed for beremagene geperpavec-svdt; 2) Documentation of clinical response to therapy (e.g., complete wound closure or other documented clinical improvement).

    Reauthorization period: 12 months.

    Initial Therapy - Prademagene zamikeracel (Zevaskyn)

    Covered when ALL of the following are met:

    Zevaskyn initial criteria: 1) Wounds associated with recessive dystrophic epidermolysis bullosa (RDEB); 2) Documented biallelic pathogenic mutations in the COL7A1 gene; 3) Positive NC1 expression of type VII collagen in skin; 4) Presence of at least one chronic wound (e.g., stage 2 wound with area ≥ 20 cm^2 and present for ≥ 3 months); 5) Presence of clinical manifestations of RDEB (extensive blistering, erosions, or scarring); 6) Medication/treatment prescribed by or in consultation with a dermatologist or wound care specialist; 7) Prescriber attests the affected wound has not been previously treated with Zevaskyn; 8) No active infection, active squamous cell carcinoma, or history of squamous cell carcinoma in the targeted wound(s).

    Prior approval limits: quantity up to 12 sheets; duration limit 6 months.

    Initial therapy (contextual — specific numeric or timing criteria not present in excerpt)

    Covered when ALL of the following are met (documented in clinical record):

    Population and diagnosis: Patient has dystrophic epidermolysis bullosa with COL7A1 mutation(s) documented in the medical record.

    Population defined by DEB with COL7A1 variants; diagnostic reports should be provided.

    Therapy corresponds to approved product: Requested therapy corresponds to an FDA‑approved product (beremagene geperpavec‑svdt topical gel or prademagene zamikeracel autologous cell therapy) intended for treatment of wounds in DEB.

    Select product per labeling and planned clinical use.

    Clinical intent and planning: Treatment is intended to improve wound healing beyond supportive care; documentation includes planned application details (treated area, expected number of cycles, surgical plan for autologous cell therapy where applicable).

    Practical details such as maximum treated area per administration and potential cycles affect clinical planning.

    Initial Therapy Coverage Criteria

    Covered when ALL of the following reflect pivotal trial inclusion characteristics

    Age consistent with studied populations: Patient age consistent with the studied populations (e.g., beremagene: ≥6 months in GEM‑3; prademagene pivotal trial enrolled older children/adults as specified in VIITAL).see study‑specific criteria

    Age criteria varied by study; confirm labeling and study details.

    Genetic confirmation: Genetically confirmed dystrophic epidermolysis bullosa with COL7A1 mutation(s) (beremagene) or two confirmed RDEB C7 mutations plus NC1+ expression (prademagene) as required by pivotal trials.genetic test report

    Molecular confirmation was required for trial enrollment.

    Wound characteristics: Wounds similar to those enrolled in pivotal trials (size, location, appearance) and meeting trial‑specified criteria where applicable.

    Pivotal trial eligibility (applied to coverage)

    Covered when ALL of the following trial-derived criteria are met

    Trial‑derived wound eligibility: Member has an open skin wound meeting ALL of the following: (1) wound area ≥ 20 cm^2; (2) wound present for ≥ 6 months; (3) Stage 2 wound defined as an open skin wound with partial‑thickness loss of dermis that has not extended through the dermis into subcutaneous tissue.area ≥20 cm^2; duration ≥6 months; Stage 2 definition applies

    These wound criteria were repeatedly specified across pivotal trial eligibility descriptions.

    Evidence-based coverage considerations

    Covered when ALL of the following are met (evidence basis):

    Population: Patient has dystrophic epidermolysis bullosa (DEB) consistent with trial populations; for beremagene the studied population had COL7A1 mutations.

    Based on pivotal RCT inclusion.

    Intervention evidence: Evidence includes single pivotal randomized trials demonstrating clinically and statistically significant improvement in wound healing and pain reduction for the specified product (beremagene: 65% vs 26% complete healing at 24 weeks; prademagene: 81% vs 16% ≥50% healing at 6 months).

    Trial effect sizes cited from GEM‑3 and VIITAL summaries.

    Safety considerations: Consider that the size of safety databases and median duration of exposure are limited; monitor for adverse reactions (e.g., itching, chills, redness, rash, cough, runny nose for beremagene; procedural pain and pruritus for prademagene).

    Safety database limitations noted in the evidence summaries.

    Initial and continuation therapy (product-specific)

    Covered when ALL required policy criteria for the specific product are met (product-specific criteria present in policy body):

    Product‑specific medical necessity: Authorization requires meeting the policy's specified criteria for the named product (e.g., Vyjuvek or Zevaskyn), including diagnosis of dystrophic epidermolysis bullosa and any product‑specific eligibility, safety, and quantity/duration limits.

    Policy updated to add criteria for Zevaskyn and additional criteria for Vyjuvek; refer to the policy sections for full product‑specific requirements and coding guidance.

    Both gene therapies in this policy are considered investigational for any indication not explicitly listed as medically necessary in this document. Specifically, beremagene geperpavec-svdt (Vyjuvek) is considered investigational when reauthorization criteria are not met, and both products remain investigational for indications outside the RDEB-associated wound indications described in this policy. (Clinical requests that do not meet the policy’s specified medical necessity criteria may be subject to denial.)

    This policy may not apply to all lines of business. State or federal mandates (for example, the Federal Employee Program) may require assessment by medical necessity rather than investigational status, and certain lines of business (including Medicare Supplement, Medicare Advantage, Medicaid, and some self‑insured groups) may follow different coverage rules or benefit exceptions. Verify member-specific plan terms before making coverage determinations.

    Clinical trial populations and safety databases are limited in size and diversity; as noted in the evidence review, enrolled populations did not reflect relevant diversity and the safety database and median duration of exposure are inadequate to fully assess harms. Use in populations not represented in the pivotal studies therefore warrants careful consideration and documentation of risks.

    A current or prior diagnosis of squamous cell carcinoma at the planned treatment site is an exclusion. Trials and the policy explicitly list current or history of squamous cell carcinoma at the treatment site as a contraindication to treatment.

    The exclusion for current or history of squamous cell carcinoma at the treatment site appears repeatedly in trial eligibility and exclusion statements and should be applied consistently when assessing medical necessity for therapy.

    Pivotal trial documents consistently excluded participants with current or prior squamous cell carcinoma at the wound site; this trial exclusion should inform eligibility assessments and may be a basis for denial if present in the medical record.

    There is no Medicare national coverage determination (NCD) for these therapies. The codes listed in this policy are provided for reference only; inclusion of a code does not guarantee member coverage or provider reimbursement. Coverage remains subject to the member’s benefit plan and applicable legal requirements.

    Use of beremagene geperpavec-svdt or prademagene zamikeracel for indications other than the wound indications in RDEB specified in this policy is considered investigational / not medically necessary. Requests for other indications should be evaluated against the member’s plan and available evidence, but by policy are not supported.

    State or federal mandates may override an investigational determination; if a mandate requires coverage of an FDA‑approved product, the intervention may be assessed only on medical necessity under the applicable mandate rather than labeled investigational in this policy.

    Limit use of these therapies to the indications and wound types evaluated in the pivotal trials. Treatments intended for wounds or indications that were not evaluated in the trials (for example, non‑DEB wounds or wounds that do not meet trial size, duration, or stage criteria) are not supported by the presented evidence and may be considered not medically necessary.

    Safety data are limited: the evidence synthesis notes that the size of the safety database and the median duration of exposure are inadequate to fully assess long‑term harms and durability of effect for prademagene zamikeracel and beremagene geperpavec‑svdt. Monitor patients and document safety follow‑up where therapy is provided.

    The policy includes CPT/HCPCS and ICD codes for reference only. Listing a code in this policy does not imply coverage; providers must confirm member benefits and obtain any required prior authorization before billing or administering therapy.

    Billing and Coding Information

    Codes table referencedmixed
    No codes listed
    Codes table referencedmixed
    No codes listed
    Covered CPT CodesCPT
    15040Harvest of skin for tissue cultured skin autograft, 100 sq cm or less
    HCPCS/J-codesHCPCS
    J3389Topical administration, prademagene zamikeracel, per treatment (Zevaskyn®) Effective 1/1/26
    J3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml (VYJUVEK™)
    J3490Unclassified drugs
    J3590Unclassified biologics
    ICD-10-CM Diagnosis CodesICD-10Covered
    Q81.2Epidermolysis bullosa dystrophica
    ICD-10-PCS Procedure CodesICD-10
    XHR0XGA - XHR7XGAPrademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy (ICD-10-PCS)
    Wound area for dosing example
    Example wound area used for dosing≥ 20 cm2 (used in dosing table and as an example wound size)
    Dose tiers by wound area<20 cm2: 4 x 10^8 PFU (0.2 mL); 20–<40 cm2: 8 x 10^8 PFU (0.4 mL); 40–60 cm2: 1.2 x 10^9 PFU (0.6 mL)
    Maximum weekly volume by age group6 months to <3 years: 0.8 mL; ≥3 years: 1.6 mL
    Wound area (repeated)
    Minimum wound area for trial-derived eligibilityAn area ≥20 cm2
    Repeated usage in pivotal trial criteria

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Obtain prior authorization (Vyjuvek and Zevaskyn)

    Prior authorization is required before initiating beremagene geperpavec-svdt (Vyjuvek) or prademagene zamikeracel (Zevaskyn). Initial authorization for Vyjuvek is for 6 months; reauthorization is 12 months when continuation criteria are met. Zevaskyn prior approval limits are quantity 12 sheets and duration 6 months.

    • Vyjuvek initial authorization period: 6 months (see product-specific criteria).
    • Vyjuvek reauthorization period: 12 months if initial criteria and clinical response documented.
    • Zevaskyn prior approval limits: Quantity 12 sheets; Duration 6 months.
    Prior Authorization

    Expect medical necessity review and eligibility checks

    Some gene-therapy products and related services are subject to medical necessity review and prior authorization; coverage may vary by line of business and state/federal mandates.

    • State or federal mandates (e.g., Federal Employee Program) may alter investigational determinations and require medical necessity review.

    Clinical and Evidence Background

    Recessive dystrophic epidermolysis bullosa (RDEB) is caused by pathogenic variants in COL7A1

    Definitions and Key Terms

    RDEB diagnostic confirmation
    Genetic confirmation requirementDocumented biallelic pathogenic mutations in COL7A1
    Protein expression requirementPositive NC1 expression of type VII collagen in skin (NC1+)
    Clinical manifestationsPresence of chronic/recurring wounds, blistering, mucosal involvement consistent with RDEB
    Chronic wound definition (example: stage 2, ≥20 cm2)
    Chronic wound definitionAt least one wound present for at least 3 months
    Example (trial-derived) for chronic woundStage 2 wound with area ≥20 cm2
    Context for eligibility
    Policy Summary
    PayerBluecross Idaho
    PolicyGene Therapies for Treatment of Wounds in Dystrophic Epidermolysis Bullosa
    Policy CodePolicy MP 5.01.47
    Change TypeMaterial additions and updates (Vyjuvek criteria expandedZevaskyn added)
    Effective DateApr 1, 2026
    Last ReviewJun 1, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain prior authorization and submit documentation confirming genetic COL7A1 mutation status, wound size/duration/stage, and product-specific limits prior to treatment.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityBilling and Coding InformationProvider Requirements, Prior Authorization, and DocumentationClinical and Evidence BackgroundDefinitions and Key Terms
    see study details (e.g., wound size/duration thresholds)

    GEM‑3 and VIITAL selected comparable wounds; verify wound selection matches trial methodology.

    Prior local therapy: Documentation of prior standard wound care or justification for trial‑type intervention (e.g., standard dressings tried or deemed unsuitable).medical record documentation

    VIITAL used standard‑of‑care dressings as the control comparator.

    Exclusions inferred from trials: Current or history of squamous cell carcinoma at the treatment site were exclusions in the pivotal trials and are excluded from coverage consideration consistent with trial populations.

    Trial exclusions repeatedly specified SCC at targeted sites.

    Criterion (area ≥20 cm2) appears repeatedly across pivotal trial enrollment descriptions
    Context in VIITAL and GEM-3Used to define target wounds for inclusion and for treated wound selection
    Wound duration (key value)
    Minimum wound duration for trial-derived eligibilityPresent for ≥6 months
    Included in repeated pivotal trial criteriaWound duration ≥6 months is consistently specified for eligible target wounds
    Used with area and stage criteriaApplied together with area ≥20 cm2 and Stage 2 wound definition
  1. This policy may not apply to certain lines of business (Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, certain self-insured groups).
  2. Prior Authorization

    Confirm genetic and diagnostic documentation in prior auth

    Prior authorization must document genetically confirmed COL7A1 mutation(s) for Vyjuvek or biallelic COL7A1 mutations with NC1+ expression for Zevaskyn, along with matching clinical diagnosis of RDEB.

    • Vyjuvek: documented COL7A1 mutation(s) and clinical manifestations consistent with dystrophic epidermolysis bullosa.
    • Zevaskyn: documented biallelic pathogenic COL7A1 mutations and positive NC1 expression in skin.
    Prior Authorization

    Verify wound meets trial eligibility (size, duration, stage)

    For prior authorization, confirm the treated wound(s) meet trial-derived eligibility: area ≥20 cm2, present for ≥6 months, and Stage 2 (open skin wound with partial-thickness loss of dermis).

    • Wound area: ≥20 cm2.
    • Wound duration: present for ≥6 months.
    • Wound stage: Stage 2—partial-thickness loss of dermis not extending into subcutaneous tissue.
    Prior Authorization

    Assess for squamous cell carcinoma exclusion

    The pivotal trials excluded patients with current or prior squamous cell carcinoma at the treatment site; evaluate targeted wound sites for any history or active SCC before approval.

    • Document absence of active squamous cell carcinoma at targeted wound(s).
    • Document no history of squamous cell carcinoma at the treatment site.
    Prior Authorization

    Include trial-aligned clinical documentation with PA

    Prior authorization must include clinical documentation aligned with pivotal trial inclusion: diagnosis, genetic test results, wound assessments, and prior standard care; cite the RCTs used as evidence when applicable.

    • Include diagnosis and genetic mutation status (COL7A1) where applicable.
    • Provide wound assessments (size, duration, stage, location) and documentation of prior standard wound care.
    • Reference clinical response endpoints when requesting reauthorization (e.g., complete wound closure).
    Prior Authorization

    Prior authorization implied for gene therapy codes

    Prior authorization is required for these gene therapies and associated specialty products; submit benefit-plan–specific authorization using the policy’s listed codes to obtain approval before treatment.

    • Relevant codes referenced in the policy (for prior auth submission) include J3401 (Vyjuvek) and J3389 (Zevaskyn), plus supporting CPT/ICD-10-PCS/ICD-10-CM codes.
    • Obtain member-specific benefit authorization prior to treatment.
    Prior Authorization

    Prescriber attestation: no prior Zevaskyn treatment

    For Zevaskyn prior approval, the prescriber must attest that the affected wound has not previously been treated with Zevaskyn.

    • Prescriber agreement required: affected wound not previously treated with Zevaskyn.
    • Prior approval limits: up to 12 sheets; duration 6 months.
    Step Therapy

    Step-therapy context — supportive care is comparator

    Step-therapy context: supportive care (wound care, pain control, infection management, nutrition) is the historical comparator rather than another prior gene therapy.

    • Document prior supportive care measures where relevant (wound dressings, infection control, pain management, nutrition).
    • There were no prior FDA-approved gene therapies used as a required prior step.
    Step Therapy

    Document prior standard wound care (step from standard care)

    Consider documentation of prior standard wound care before advanced therapies; the VIITAL trial compared prademagene to standard-of-care dressings and prior appropriate wound care may be relevant to authorization.

    • Document that standard-of-care wound dressings and appropriate local care were tried or considered for the target wound(s).
    • For prademagene (VIITAL), control arm received standard wound dressings; use of prior standard care supports alignment with trial populations.
    Note
    Step Therapy

    No mandated pharmacologic step therapy in policy excerpts

    No formal step therapy algorithm is specified in these excerpts; the policy does not mandate a pharmaceutical prior-step but trials required consideration of standard wound care.

    • No explicit prior pharmacologic step therapy requirements present in policy excerpts.
    • Documentation of prior standard wound care is suggested but not defined as a required step-therapy drug trial.
    Note

    Follow product-specific policy criteria prior to approval

    Follow the policy’s product-specific criteria and limits for authorization; recent policy additions include operationalized criteria and limits for Zevaskyn and expanded Vyjuvek criteria.

    • Refer to the policy sections for product-specific eligibility and limits prior to submitting authorization requests.
    • Policy updates (April 2025 additions) added Zevaskyn criteria and Vyjuvek clarifications.
    Documentation Required

    Submit required diagnostic documentation (genetics, NC1, wounds)

    Required diagnostic documentation for prior authorization includes genetic confirmation of biallelic COL7A1 mutations, positive NC1 expression in skin, and presence of chronic wound(s) consistent with the listed trial examples.

    • Genetic test report documenting biallelic pathogenic COL7A1 mutations.
    • Skin biopsy or report showing NC1+ expression where required (per product criteria).
    • Wound documentation (size, duration, stage) consistent with chronic wound definitions.
    Documentation Required

    Provide Vyjuvek safety documentation (pregnancy, infection, SCC)

    Safety documentation required for Vyjuvek: confirm the patient is not pregnant or breastfeeding and that there is no active infection or active/history of squamous cell carcinoma in the targeted wound(s).

    • Document pregnancy and breastfeeding status.
    • Document absence of active infection in targeted wound(s).
    • Document absence of active or prior squamous cell carcinoma at targeted wound(s).
    Documentation Required

    Document intended therapy details and expected treated area

    Include therapy-specific procedural details in clinical documentation: for Vyjuvek, planned topical application and dosing; for Zevaskyn, autologous cell manufacturing and planned surgical application and expected treated area/cycles.

    • Describe intended administration: topical Vyjuvek dosing per label; Zevaskyn surgical application and number of sheets to be used.
    • For Zevaskyn, document expected treated area and planned number of cycles if relevant to approval limits.
    Documentation Required

    Provide comprehensive clinical documentation (age, wounds, prior care)

    Required clinical documentation should include patient age, genetic confirmation or RDEB diagnosis, wound characteristics (size, location, duration, stage), and prior treatments to match pivotal trial populations.

    • Age consistent with studied populations (e.g., Vyjuvek ≥6 months; VIITAL enrollment criteria vary).
    • Wound characteristics: area, duration, stage, and location.
    • Prior treatments and supportive care measures documented in the medical record.
    Documentation Required

    Document wound size, duration, and stage explicitly

    Document wound size (area ≥20 cm2), duration (present for ≥6 months), and stage (Stage 2 open skin wound with partial-thickness loss of dermis) when applicable to the requested treatment.

    • Wound area: ≥20 cm2 is repeatedly specified in trial eligibility statements.
    • Wound duration: present for ≥6 months.
    • Stage 2 definition: partial-thickness loss of dermis not extending into subcutaneous tissue.
    Documentation Required

    Documentation note: Stage 2 wound definition required

    Note that trial descriptions consistently used Stage 2 wounds: define and document Stage 2 wounds as open skin wounds with partial-thickness loss of dermis that have not extended through the dermis into subcutaneous tissue.

    • Ensure medical record describes wound depth consistent with Stage 2 definition used in trials.
    • Record photographic or descriptive evidence supporting Stage 2 status when available.
    Documentation Required

    Confirm and document complete wound healing on consecutive visits

    When using wound healing as an endpoint for reauthorization, confirm complete wound healing at two consecutive visits (at least 2 weeks apart) as specified in trial protocols.

    • Complete wound healing defined as re-epithelialization with no drainage or erosion and only minor crusting.
    • Confirmation required at two consecutive visits (e.g., 2 weeks apart) per trial endpoints.
    Billing Rule

    Include required coding documentation with PA

    Submit appropriate diagnosis and procedure codes with the prior authorization request to support coverage (e.g., Q81.2 for dystrophic epidermolysis bullosa) and the specific J-code for the product administered.

    • Include ICD-10-CM diagnosis Q81.2 (Epidermolysis bullosa dystrophica).
    • Include relevant HCPCS/J-codes such as J3401 (Vyjuvek) or J3389 (Zevaskyn) where applicable.
    Denial Risk

    Coverage risk: investigational if criteria not met

    Beremagene (Vyjuvek) is considered investigational when continuation criteria are not met and both therapies are investigational for indications not explicitly listed; lack of required documentation may lead to investigational/coverage denial.

    • If reauthorization criteria (including documented clinical response) are not met, Vyjuvek is considered investigational.
    • Use outside the specified RDEB wound indications is investigational per the policy.
    Denial Risk

    Verify benefit exceptions for the member’s plan

    Benefit exceptions apply — this policy may not apply to certain lines of business (e.g., Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, and certain self-insured groups), which can affect coverage adjudication.

    • Verify member’s line of business and any state/federal mandates before relying on policy coverage determinations.
    • Benefit exceptions may result in different review pathways or denials.
    Denial Risk

    Coverage risk if wound or diagnosis outside trial criteria

    Treatment requests for wounds that do not meet the trial criteria (e.g., wounds smaller than 20 cm2, present <6 months, or not Stage 2) or lacking genetic confirmation risk denial for failure to meet coverage criteria.

    • Use outside studied inclusion criteria (size, duration, genetic confirmation) may be denied.
    • Provide robust documentation if requesting coverage outside trial-like populations.
    Denial Risk

    Exclusion: squamous cell carcinoma at treatment site

    Presence of current or prior squamous cell carcinoma at the treatment site is an explicit exclusion in trial descriptions and is a basis for denial of coverage.

    • Document absence of SCC at targeted site; an active or prior SCC at the site may trigger denial.
    • Trials repeatedly listed SCC at the treatment site as an exclusion.
    Denial Risk

    Apply trial exclusion for SCC at treatment site

    The pivotal trials explicitly excluded participants with current or history of squamous cell carcinoma at the treatment site; apply this exclusion when evaluating eligibility for treatment.

    • Use trial exclusions to inform eligibility determinations for prior authorization.
    • If SCC history is present at the site, deny or consider noncoverage per policy exclusion.
    Denial Risk

    Contraindication/exclusion: SCC at targeted wound site

    Current or history of squamous cell carcinoma at the treatment site is documented across trial descriptions as an exclusion and would be a contraindication for these therapies; absence of SCC must be documented.

    • Ensure medical record explicitly states no active or prior SCC at the wound site.
    • If SCC is present or history is documented at the site, the request is expected to be denied.
    Billing Rule

    Coding inclusion disclaimer — codes don’t guarantee coverage

    Inclusion of codes in the policy’s coding table is for reference only and does not guarantee coverage or provider reimbursement; coverage decisions remain subject to member-specific benefit plan terms.

    • The presence of HCPCS/CPT/ICD codes in the policy does not imply automatic coverage.
    • Always verify member benefits and obtain prior authorization per plan requirements.
    Used with genetic and clinical criteria for therapy coverage
    Dystrophic epidermolysis bullosa (DEB) definition
    DefinitionA clinically and genetically heterogeneous skin fragility disorder caused by COL7A1 variants leading to defective type VII collagen and anchoring fibrils, resulting in blistering and scarring
    Inheritance and severityCan be inherited dominantly or recessively; recessive forms (RDEB) are generally more severe
    ComplicationsMay include malnutrition, anemia, infection, and increased risk of skin cancer
    Beremagene geperpavec-svdt (Vyjuvek) definition
    Therapy descriptionBeremagene geperpavec-svdt (Vyjuvek) is a nonintegrating, replication-defective HSV-1–based topical vector engineered to express human type VII collagen (COL7) to transduce keratinocytes and fibroblasts
    AdministrationTopical application once weekly by a healthcare professional with dosing varied by wound area and patient age
    ImplicationNonintegrating design reduces insertional mutagenesis risk but requires repeated dosing to maintain effect
    Prademagene zamikeracel (Zevaskyn) definition
    Therapy descriptionPrademagene zamikeracel (Zevaskyn) is an autologous cell–based therapy: patient skin biopsy–derived cells transduced ex vivo with a replication-incompetent retroviral vector containing full-length COL7A1, manufactured as sheets for surgical application
    Product specifics and limitsUp to 12 sheets may be manufactured per patient; prior approval limits note quantity 12 sheets and duration 6 months
    Procedure complexityRequires biopsy, ex vivo manufacturing, and surgical application often with inpatient stay and anesthesia precautions due to fragile skin
    Complete wound closure definition
    Complete wound closure definition100% wound closure (re-epithelialization) of the exact baseline wound area without drainage or erosion and only minor crusting
    Confirmation requirementWound closure must be confirmed at two consecutive study visits (e.g., 2 weeks apart) when used as an endpoint
    Use in authorizationDocumented complete closure is acceptable evidence of clinical response for reauthorization decisions
    Responder (VIITAL co-primary)
    Responder (VIITAL co-primary) definitionProportion of randomized wound pairs with at least 50% healing at month 6 with confirmation of wound healing two weeks later
    Endpoint confirmationSuccess at month 6 must be confirmed at least 2 weeks later per trial protocol
    Clinical relevanceUsed as a co-primary endpoint in VIITAL to assess prademagene effectiveness
    Stage 2 wound (as used here)
    Stage 2 wound definitionAn open skin wound with partial-thickness loss of dermis that has not extended through the dermis into subcutaneous tissue
    Role in eligibilityStage 2 designation used with area and duration to define target wounds for trials and coverage
    Consistent trial wordingThis definition is repeated throughout pivotal trial eligibility descriptions
    Stage 2 wound (duplicate definition entry)
    Stage 2 wound (duplicate entry)Open skin wound with partial-thickness loss of dermis that has not extended through the dermis into subcutaneous tissue
    Repeated useRepeated across documents to emphasize consistent meaning for enrollment and coverage criteria
    Applied with area/durationUsed alongside area ≥20 cm2 and duration ≥6 months for eligibility
    Complete wound healing (confirmation at two visits)
    Complete wound healing confirmationRe-epithelialization with no drainage or erosion and only minor crusting; confirmation required at two consecutive visits
    Trial endpoint useTrials required confirmation of healing at specified visits (e.g., month 6 confirmation 2 weeks later)
    Documentation implicationUse this confirmation standard when documenting outcomes for reauthorization or effectiveness assessment
    Vyjuvek (term mapping)
    Term mapping: VyjuvekVyjuvek = beremagene geperpavec-svdt (trade name mapping to generic)
    Source guidancePrescribing label referenced in policy references (Vyjuvek prescribing label cited)
    Coding relationJ3401 maps to Beremagene geperpavec-svdt for topical administration per codes table
    Zevaskyn (term mapping)
    Term mapping: ZevaskynZevaskyn = prademagene zamikeracel (trade name mapping to generic)
    Product codingJ3389 maps to prademagene zamikeracel per the codes table (effective 1/1/26)
    Regulatory noteZevaskyn was added to policy following FDA approval (April 2025) and has prior approval limits (12 sheets, 6 months)